You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Adiabatic Circuits for Ultra-Low Energy Consumption

    SBC: INDIANA INTEGRATED CIRCUITS LLC            Topic: AF18BT013

    Adiabatic reversible logic provides a way to dramatically reduce power dissipation by recovering the energy used to encode information, rather than dissipating the energy to heat, as is done in conventional CMOS. For Phase I we will design test circuits that will evaluate the energy savings in adiabatic reversible logic, as compared to conventional logic. In addition to these smaller circuits, a M ...

    STTR Phase I 2019 Department of DefenseAir Force
  3. A new generation of targeted therapeutics for the treatment of cancer

    SBC: NERX BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Probiotic Platform to Treat Necrotizing Enterocolitis

    SBC: MONON BIOVENTURES LLC            Topic: 300

    PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. A simple assay system for rapid detection of circulating tumor cells

    SBC: TELOVISION, LLC            Topic: NCI

    DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Bayesian Inference of Spacecraft Geometry and Pose

    SBC: VISION SYSTEMS INC            Topic: AF17AT007

    Space platforms are complex dynamical systems and there are many reasons to model them from ground telescope imagery as well as from space-based sensor platforms. One key motivation is to determine the operational state and configuration of the vehicle. Key questions such as did the solar panels fail to deploy, did the object begin to tumble unexpectedly may be addressed by a sufficiently detaile ...

    STTR Phase I 2017 Department of DefenseAir Force
  7. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression

    SBC: Aingeal, LLC            Topic: 101

    Major depressive disorder is a debilitating mood disorder that affects ~7% of US adults in their lifetime, costing the U.S. economy more than $200 billion a year. Drugs that increase monoaminergic signaling are the mainstay of depression therapy, but have a delayed onset of action and are only effective in about 50% of affected patients. Aberrant brain-derived neurotrophic factor (BDNF) signaling ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Novel Therapeutic for Hyperthyroidism

    SBC: Medosome Biotec, LLC            Topic: NIDDK

    GravesdiseaseGDis the most common cause of hyperthyroidism and is caused by stimulation of the thyroid stimulating hormone receptorTSHRby thyroid receptor stimulating antibodiesTSAbsTreatment of GD involves antithyroid medication therapyradioactive iodineand surgeryAt the presentfew alternative forms of therapy for GD are available or are in developmentThe ability to block TSHR action may also be ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Stem Cell-derived Cell-free Therapeutic for Stress Urinary Incontinence

    SBC: NeuroFx, Inc.            Topic: 400

    Abstract Stress urinary incontinenceSUIcan result from a combinatorial neuromuscular injury to the pudendal nerve and the muscle it innervatesthe external urethral sphincterEUScompounded by the biochemical effects of agingThe mechanisms of SUI development include incomplete pudendal nerve regeneration and EUS sphincter repair from the maternal polytrauma of childbirth as well as biochemical change ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government